PD-1抑制剂疗法：黑色素瘤护理倡议组织教员关于不良事件管理的共识声明
PD-1 Inhibitor Therapy: Consensus Statement From the Faculty of the Melanoma Nursing Initiative on Managing Adverse Events .
作者信息
McGettigan Suzanne, Rubin Krista M
机构信息
University of Pennsylvania.
Massachusetts General Hospital Cancer Center.
出版信息
Clin J Oncol Nurs. 2017 Aug 1;21(4 Suppl):42-51. doi: 10.1188/17.CJON.S4.42-51.
BACKGROUND: Programmed cell death protein 1 (PD-1) inhibitor therapies are now a standard treatment for advanced melanoma and other tumor types. The immune-related adverse events (irAEs) associated with PD-1 inhibitor therapy are drastically different from the AEs associated with chemotherapy. Because these irAEs reflect immune system activation rather than side effects of therapy, nurses should be cognizant of the range of organ systems potentially affected as well as likely clinical presentations. .
OBJECTIVES: This article presents consensus statements to guide nurses in the recognition and management of irAEs associated with PD-1 inhibitor monotherapy for advanced melanoma. .
METHODS: Members of the Melanoma Nursing Initiative discussed the current literature and clinical experience regarding nursing interventions related to irAEs associated with PD-1 inhibitor therapy. .
FINDINGS
The care step pathways provided for select irAEs represent a proactive, comprehensive nursing care plan to support optimal outcomes for patients receiving PD-1 inhibitor therapy.
背景
程序性细胞死亡蛋白1（PD-1）抑制剂疗法目前是晚期黑色素瘤和其他肿瘤类型的标准治疗方法。与PD-1抑制剂治疗相关的免疫相关不良事件（irAE）与化疗相关的不良事件截然不同。由于这些irAE反映的是免疫系统激活而非治疗副作用，护士应了解可能受影响的器官系统范围以及可能的临床表现。
目的
本文提出共识声明，以指导护士识别和管理与晚期黑色素瘤PD-1抑制剂单药治疗相关的irAE。
方法
黑色素瘤护理倡议组织的成员讨论了有关与PD-1抑制剂治疗相关的irAE护理干预措施的当前文献和临床经验。
结果
为特定irAE提供的护理步骤路径代表了一个积极主动、全面的护理计划，以支持接受PD-1抑制剂治疗的患者获得最佳治疗效果。
Zotero 插件